---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-011738"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:38:16.558626+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica raises up to $55M in private placement; $20.4M upfront from new and existing investors

## Summary
- Upfront gross proceeds $20.4M from sale of 5.1M shares and pre-funded warrants to purchase 351,352 shares at $3.70/share.
- Additional up to ~$34.2M possible if Tranche A ($5.36/share) and Tranche B ($7.15/share) warrants are exercised in cash.
- Tranche A warrants expire earlier of 30 days after topline AP data or Dec 31, 2024; Tranche B earlier of 30 days after AKI data or Dec 31, 2026.
- Cash, equivalents and short-term investments were $11.2M as of Dec 31, 2023 (preliminary); proceeds expected to fund Phase 2 trials in AP and AKI.
- New investors include Deerfield Management, Soleus Capital, Stonepine Capital, Aisling Capital; JonesTrading as placement agent.

## SEC filing metadata
- accession: 0001193125-24-011738
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/0001193125-24-011738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/d738337d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-011738
- JSON: https://secwatch.observer/filing/0001193125-24-011738.json
- Plain text: https://secwatch.observer/filing/0001193125-24-011738.txt

## Key facts
- Material Agreements
  CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at upfront gross proceeds from the Private Placement of $20.4 million (effective 2024-01-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: upfront gross proceeds from the Private Placement of $20.4 million
  - Effective: 2024-01-19
  source text: On January 19, 2024, CalciMedica, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000119312524011738/0001193125-24-011738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.